Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18762513 | 0.80 | HMGCR (0.48) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL20908224 | 0.76 | TET2 (0.33) | TET2 | |
| SCHEMBL29059482 | 0.75 | HMGCR (0.31) | HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL3697055 | 0.71 | HMGCR (0.41) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL19359063 | 0.69 | HMGCR (0.46) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL8874275 | 0.69 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL28976503 | 0.68 | PIK3CD (0.31) | — | |
| SCHEMBL27770098 | 0.67 | TSHR (0.42) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL28113103 | 0.67 | TSHR (0.42) | HMGCRCHRM1TBXA2RADRA1ACYP2D6 | |
| SCHEMBL3230536 | 0.66 | OR51E2 (0.40) | OR51E2TET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2019075291-A1 | 1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078959-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, FURIN | HMGCR 1256/4885CHRM1 4851/4885TBXA2R 4105/4885 |
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | HMGCR 1256/4885CHRM1 4851/4885TBXA2R 4105/4885 |
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | HMGCR 1256/4885CHRM1 4851/4885TBXA2R 4105/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | HMGCR 906/4885CHRM1 4844/4885TBXA2R 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.